• Sera Prognostics’ third-quarter 2026 net loss widened year over year to $8.05 million.
• Revenue more than doubled year over year to $42,000, although a higher mix of low- or non-reimbursed tests pressured average selling prices.
• Operating expenses fell 11% from the second quarter to $8.93 million following cost reductions implemented in June.
• Florida became the second state providing Medicaid coverage for PreTRM, bringing total covered Medicaid lives to approximately 7 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sera Prognostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA88679) on November 04, 2026, and is solely responsible for the information contained therein.